Inactivating PLXNB1 has shown a shift in the immune landscape of tumor microenvironments towards an antitumor response; however, angiogenesis is not affected since SEMA4D can bind to alternative receptors [263]. The gene discussed is SEMA4D; the disease is neoplasm.